Mitochondrial amidoxime reducing component 2 Antibody / mARC2 / MTARC2

Catalytic component of the benzamidoxime prodrug-converting complex, a complex required to reduce N-hydroxylated structures, such as benzamidoxime prodrug. Benzamidoxime is an amidine prodrug produced by N-hydroxylation which is used to enhance bioavailability and increase intestinal absorption. It is then reduced into benzamidine, its active amidine, by the benzamidoxime prodrug-converting complex.

Product Specifications

CAS Number

9007-83-4

Specifications

Western blot: 1:500-1:1000, Flow cytometry: 1:10-1:50 (1x10e6 cells), Immunohistochemistry (FFPE) : 1:50-1:100

UniProt

Q969Z3

Host

Rabbit

Reactivity

Human

Immunogen

A portion of amino acids 270-300 from the human protein was used as the immunogen for the Mitochondrial amidoxime reducing component 2 antibody.

Clonality

Polyclonal

Isotype

Applications

WB, FACS, IHC-P

Purity

Antigen affinity purified

Format

Purified

Buffer

In 1X PBS, pH 7.4, with 0.09% sodium azide

Reconstitution

Aliquot the Mitochondrial amidoxime reducing component 2 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Limitations

This Mitochondrial amidoxime reducing component 2 antibody is available for research use only.

Storage Conditions

Aliquot the Mitochondrial amidoxime reducing component 2 antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.

Formulation

In 1X PBS, pH 7.4, with 0.09% sodium azide

Applications Notes

The stated application concentrations are suggested starting points. Titration of the Mitochondrial amidoxime reducing component 2 antibody may be required due to differences in protocols and secondary/substrate sensitivity.

Location

Cytoplasmic

Image Legend

IHC testing of FFPE human lung carcinoma tissue with Mitochondrial amidoxime reducing component 2 antibody. HIER: steam section in pH6 citrate buffer for 20 min and allow to cool prior to staining.